Intangible Assets

9 Months Ended

Jun. 30, 2017

Goodwill And Intangible Assets Disclosure [Abstract]

Intangible Assets

NOTE 5. INTANGIBLE ASSETS

Intangible assets subject to amortization include patents and a license agreement capitalized as part of the Novartis RNAi asset acquisition in March 2015. The license agreement associated with the Novartis RNAi asset acquisition is being amortized over the estimated life remaining at the time of acquisition, which was 21 years, and the accumulated amortization of the asset is approximately $346,279.  The patents associated with the Novartis RNAi asset acquisition are being amortized over the estimated life remaining at the time of acquisition, which was 14 years, and the accumulated amortization of the assets is approximately $3,621,389.  Amortization expense for the three and nine months ended June 30, 2017 was $425,107 and $1,275,322, respectively. Amortization expense for the three and nine months ended June 30, 2016 was $425,107 and $1,289,206, respectively.  Amortization expense is expected to be approximately $425,107 for the remainder of fiscal year2017, $1,700,429 in 2018, $1,700,429 in 2019, $1,700,429 in 2020, $1,700,429 in 2021, $1,700,429 in 2022, and $11,962,294 thereafter.

The following table provides details on the Company’s intangible asset balances:

	Intangible assets subject to amortization
Balance at September 30, 2016		$	22,164,868
Impairment			-
Amortization			(1,275,322	)
Balance at June 30, 2017		$	20,889,546